Sex, Race, Age Disparities in Survival for HPV-Linked Cancer

This article originally appeared here.
Share this content:
Sex, Race, Age Disparities in Survival for HPV-Linked Cancer
Sex, Race, Age Disparities in Survival for HPV-Linked Cancer

TUESDAY, Nov. 28, 2017 (HealthDay News) -- For patients with human papillomavirus (HPV)-associated cancers, there are large disparities in survival based on sex, race, and age, according to a study published online Nov. 6 in Cancer.

Hilda Razzaghi, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined high-quality data from 27 population-based cancer registries covering about 59 percent of the U.S. population to examine how relative survival varies for HPV-associated cancers. The analyses were limited to invasive cancers diagnosed during 2001 through 2011, and followed through 2011. Five-year relative survival was calculated from diagnosis to death.

The researchers found that the five-year age-standardized relative survival rates for cervical carcinomas, vaginal squamous cells carcinomas (SCCs), vulvar SCCs, penile SCCs, anal SCCs, rectal SCCs, and oropharyngeal SCCs were 64.2, 52.8, 66.0, 47.4, 65.9, 56.2, and 51.2 percent, respectively. Compared with black patients, white patients had consistently higher five-year relative survival for all HPV-associated cancers across all age groups, with the greatest differences by race seen for oropharyngeal SCCs among those aged <60 years and among those aged 40 to 49 years with penile SCCs.

"There are large disparities in relative survival among patients with HPV-associated cancers by sex, race, and age," the authors write. "HPV vaccination and improved access to screening (of cancers for which screening tests are available) and treatment, especially among groups that experience higher incidence and lower survival, may reduce disparities in survival from HPV-associated cancers."

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab &#43; Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »